Corium International, Inc. (CORI) PT Set at $10.00 by Cantor Fitzgerald
Corium International, Inc. (NASDAQ:CORI) received a $10.00 price objective from analysts at Cantor Fitzgerald in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 184.90% from the company’s current price.
CORI has been the subject of several other reports. FBR & Co reaffirmed a “buy” rating and set a $18.00 price objective on shares of Corium International in a report on Tuesday, November 22nd. Leerink Swann reaffirmed a “buy” rating on shares of Corium International in a report on Wednesday, January 4th. Jefferies Group LLC set a $9.00 price objective on shares of Corium International and gave the stock a “buy” rating in a report on Thursday, November 24th. Zacks Investment Research raised shares of Corium International from a “sell” rating to a “hold” rating in a report on Tuesday, November 8th. Finally, Needham & Company LLC decreased their price objective on shares of Corium International from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $10.21.
Shares of Corium International (NASDAQ:CORI) traded up 10.03% during midday trading on Tuesday, hitting $3.51. Corium International has a 52-week low of $2.67 and a 52-week high of $8.33. The stock’s market cap is $102.58 million. The firm has a 50 day moving average price of $3.61 and a 200 day moving average price of $4.81.
Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Monday, February 13th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.04. The firm had revenue of $7 million for the quarter, compared to the consensus estimate of $8.07 million. Corium International had a negative return on equity of 359.24% and a negative net margin of 116.26%. Equities analysts anticipate that Corium International will post ($1.61) earnings per share for the current year.
This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of United States and international copyright law. The original version of this report can be read at http://www.watchlistnews.com/corium-international-inc-cori-pt-set-at-10-00-by-cantor-fitzgerald/1121356.html.
An institutional investor recently raised its position in Corium International stock. RTW Investments LLC boosted its stake in Corium International, Inc. (NASDAQ:CORI) by 3.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 852,961 shares of the biopharmaceutical company’s stock after buying an additional 24,629 shares during the period. Corium International makes up approximately 1.0% of RTW Investments LLC’s portfolio, making the stock its 21st largest position. RTW Investments LLC owned approximately 3.83% of Corium International worth $2,960,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 67.75% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.